Idiopathic Hypersomnia Clinical Trial
Official title:
a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial
Idiopathic hypersomnia (IH) is a chronic disabling disorder characterized by excessive daytime sleepiness (EDS), prolonged nighttime sleep and sleep inertia. IH is a rare disorder, estimated around 0.05%, yet its true prevalence remains unknown. Disease onset occurs most often during young adulthood and is accompanied by severe social, professional and economic impairments, resulting in risk of accident and a loss in patient's quality of life. There are no ANSM (or FDA-) approved treatments for IH symptoms. IH shares common features with delayed sleep-wake phase disorder (DSWPD) which is a chronic circadian rhythm disorder which occurs as in IH during young adulthood. The combination of evening melatonin and morning bright light therapy is the most effective validated chronotherapy in DSWPD.Moreover, bright light therapy has direct effects and is known to increase daytime alertness and to improve mood. Melatonin is empirically used in routine clinical practice in patients with IH and French and European recommendations mention melatonin as a possible treatment of sleep inertia in IH. . Our goal is to bring a proof of concept of a safe therapeutic practice for IH combining exogenous melatonin and bright light therapy in
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04026958 -
Clarithromycin Mechanisms in Hypersomnia Syndromes
|
Phase 2 | |
| Completed |
NCT02512588 -
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
|
Phase 2 | |
| Completed |
NCT01183312 -
Flumazenil for the Treatment of Primary Hypersomnia
|
Phase 1/Phase 2 | |
| Completed |
NCT03597555 -
Sodium Oxybate in Idiopathic Hypersomnia
|
Phase 2/Phase 3 | |
| Completed |
NCT03356938 -
The Role of the Circadian System in Neurological Sleep-wake Disorders
|
N/A | |
| Completed |
NCT03533114 -
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
|
Phase 3 | |
| Active, not recruiting |
NCT03542851 -
A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia
|
Phase 2 | |
| Completed |
NCT05156047 -
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
|
Phase 3 | |
| Enrolling by invitation |
NCT05371483 -
Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
|
||
| Completed |
NCT04827329 -
Anesthetic Management of Patients With Chronic Sleep Disorders
|
||
| Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
| Recruiting |
NCT05875974 -
Ph4 PSG Combined JZP258-407
|
Phase 4 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT01146600 -
Clarithromycin for the Treatment of Hypersomnia
|
Phase 2 | |
| Recruiting |
NCT04330963 -
International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
|
||
| Completed |
NCT04091438 -
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
|
Phase 1 | |
| Recruiting |
NCT05615584 -
Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence
|
N/A | |
| Recruiting |
NCT05837091 -
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
|
Phase 4 | |
| Recruiting |
NCT05321355 -
Mainz Register of Patients With Sleep Disorders
|
||
| Active, not recruiting |
NCT05668754 -
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH
|
Phase 2 |